Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and In Vivo bioavailability

Journal of Pharmaceutical Sciences

Volumn 101, Issue 10, 2012, Pages 3763-3778

  Miller, Maria A ^a   Khan, Tarik A ^a   Kaczorowski, Kevin J ^a   Wilson, Brian K ^a   Dinin, Aileen K ^a   Borwankar, Ameya U ^a   Rodrigues, Miguel A ^a   Truskett, Thomas M ^a   Johnston, Keith P ^a   Maynard, Jennifer A ^a  

^a The University of Texas at Austin   (United States)

Author keywords

Formulation; Freeze drying lyophilization; Preclinical pharmacokinetics; Protein aggregation; Protein delivery; Stabilization

Indexed keywords

1 METHYL 2 PYRROLIDINONE; CARBON; IMMUNOGLOBULIN G2A ANTIBODY; MACROGOL; MONOCLONAL ANTIBODY 1B7; NANOPARTICLE; TREHALOSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; FEMALE; FREEZE DRYING; FREEZING; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MOUSE; NONHUMAN; PARTICLE SIZE; VISCOSITY;

EID: 84865366743     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23256     Document Type: Article

References (74)

1. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. 2005. Monoclonal antibody successes in the clinic. Nat Biotechnol 23(9):1073-1078.
2. Nelson AL, Dhimolea E, Reichert JM. 2010. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Disc 9:767-774.
3. Trevino SR, Scholtz JM, Pace CN. 2008. Measuring and increasing protein solubility. J Pharm Sci 97(10):4155-4166.
4. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. 2009. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 106(29):11937-11942.
5. Maynard JA, Maassen CB, Leppla SH, Brasky K, Patterson JL, Iverson BL, Georgiou G. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 20(6):597-601.
6. Frokjaer S, Otzen DE. 2005. Protein drug stability: A formulation challenge. Nat Rev Drug Discov 4:298-306.
7. Yang MX, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, Margolin AL. 2003. Crystalline monoclonal antibodies for subcutaneous delivery. Proc Natl Acad Sci U S A 100(12):6934-6939.
8. Anonymous. 2010. RITUXAN® (Rituximab) full prescribing information. South San Francisco, California: Genentech, Inc.
9. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-1402.
10. Dani B, Platz R, Tzannis ST. 2007. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration. J Pharm Sci 96(6):1504-1517.
11. Neal BL, Asthagiri D, Lenhoff AM. 1998. Molecular origins of osmotic second virial coefficients of proteins. Biophys J 75:2469-2477.
12. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. 2003. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci 12:903-913.
13. Harn N, Allan C, Oliver C, Middaugh CR. 2007. Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability. J Pharm Sci 96(3):532-546.
14. Young TM, Roberts CJ. 2009. Structure and thermodynamics of colloidal protein cluster formation: Comparison of square-well and simple dipolar models. J Chem Phys 131:125104.
15. Liu J, Nguyen MDH, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci 94(9):1928-1940.
16. Sear RP. 2006. Interactions in protein solutions. Curr Opin Colloid Interface Sci 11:35-39.
17. Curtis RA, Prausnitz JM, Blanch HW. 1998. Protein-protein and protein-salt interactions in aqueous protein solutions containing concentrated electrolytes. Biotechnol Bioeng 57(1):11-21.
18. Johnston KP, Maynard JA, Truskett TM, Borwankar A, Miller MA, Wilson B, Dinin A, Khan T, Kaczorowski KJ. 2012. Concentrated dispersions of equilibrium protein nanoclusters that reversibly dissociate into active monomers. ACS Nano 6(2):1357-1369.
19. Scherer TM, Liu J, Shire SJ, Minton AP. 2010. Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering. J Phys Chem B 114:12948-12957.
20. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. 1998. A transient expansion of the native state precedes aggregation of recombinant human interferon-γ. Proc Natl Acad Sci U S A 95:14142-14146.
21. Wang W, Nema S, Teagarden D. 2010. Protein aggregation-Pathways and influencing factors. Int J Pharm 390(2):89-99.
22. Miller MA, Engstrom JD, Ludher BS, Johnston KP. 2010. Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles. Langmuir 26(2):1067-1074.
23. Defelippis MR, Akers MJ. 2000. Peptides and proteins as parenteral suspensions: An overview of design, development, and manufacturing considerations. In Pharmaceutical formulation development of peptides and proteins; Frokjaer S, Hovgaard L, Eds. Philadelphia, Pennsylvania: Taylor & Francis Ltd., pp 113-143.
24. Shenoy B, Wang Y, Shan W, Margolin AL. 2001. Stability of crystalline proteins. Biotechnol Bioeng 73(5):358-369.
25. Foster TP, Moseley WM, Caputo JF, Alaniz GR, Leatherman MW, Yu X, Claflin WH, Reeves DR, Cleary DL, Zantello MR, Krabill LF, Wiest JR. 1997. Sustained elevated serum somatotropin concentrations in Holstein steers following subcutaneous delivery of a growth hormone releasing factor analog dispersed in water, oil or microspheres. J Controlled Release 47:91-99.
26. Putney SD, Burke PA. 1998. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 16:153-157.
27. Fu K, Klibanov AM, Langer R. 2000. Protein stability in controlled-release systems. Nat Biotechnol 18:24-25.
28. Tae G, Kornfield JA, Hubbell JA. 2005. Sustained release of human growth hormone from in situ forming hydrogels using self-assembly of fluoroalkyl-ended poly(ethylene glycol). Biomaterials 26(25):5259-5266.
29. Mok H, Park TG. 2008. Water-free microencapsulation of proteins within PLGA microparticles by spray drying using PEG-assisted protein solubilization technique in organic solvent. Eur J Pharm Biopharm 70(1):137-144.
30. Zhu G, Mallery SR, Schwendeman SP. 2000. Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide). Nat Biotechnol 18:52-57.
31. Gombotz WR, Pettit DK. 1995. Biodegradable polymers for protein and peptide drug delivery. Bioconjug Chem 6(4):332-351.
32. Ye M, Kim S, Park K. 2010. Issues in long-term protein delivery using biodegradable microparticles. J Controlled Release 146(2):241-260.
33. Singh M, Li X-M, McGee JP, Zamb T, Koff W, Wang CY, O'Hagan DT. 1997. Controlled release microparticles as a single dose hepatitis B vaccine: Evaluation of immunogenicity in mice. Vaccine 15(5):475-481.
34. Cheung MS, Klimov D, Thirumalai D. 2005. Molecular crowding enhances native state stability and refolding rates of globular proteins. Proc Natl Acad Sci U S A 102(13):4753-4758.
35. Shen VK, Cheung JK, Errington JR, Truskett TM. 2009. Insights into crowding effects on protein stability from coarse-grained model. J Biomech Eng 131:071002.
36. Sato H, Sato Y. 1990. Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect Immun 58(10):3369-3374.
37. Sutherland JN, Maynard JA. 2009. Characterization of a key neutralizing epitope on pertussis toxin recognized by the monoclonal antibody 1B7. Biochemistry 48(50):11982-11993.
38. Strickley RG. 2004. Solubilizing excipients in oral and injectable formulations. Pharm Res 21(2):201-230.
39. Ryoo W, Webber SE, Johnston KP. 2003. Water-in-carbon dioxide microemulsions with methylated branched hydrocarbon surfactants. Ind Eng Chem Res 42:6348-6358.
40. Sutherland JN, Chang C, Yoder SM, Rock MT, Maynard JA. 2011. Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization. Clin Vaccine Immunol 18(6):954-962.
41. Gillenius P, Jaatmaa E, Askelof P, Granstrom M, Tiru M. 1985. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand 13(1):61-66.
42. Carpenter JF, Chang BS, Garzon-Rodrigues W, Randolph TW. 2002. Rational design of stable lyophilized protein formulations: Theory and practice. In Pharmaceutical biotechnology; Carpenter JF, Manning MC, Eds. Vol. 13. Rational design of stable protein formulations. New York: Kluwer, pp 109-133.
43. Engstrom JD, Simpson DT, Cloonan C, Lai ES, Williams III RO, Kitto GB, Johnston KP. 2007. Stable high surface area lactate dehydrogenase particles produced by spray freezing into liquid nitrogen. Eur J Pharm Biopharm 65:163-174.
44. Chen B, Bautista R, Yu K, Zapata GA, Mulkerrin MG, Chamow SM. 2003. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm Res 20(12):1952-1960.
45. Engstrom JD, Lai ES, Ludher BS, Chen B, Milner TE, Williams RO, III, Kitto GB, Johnston KP. 2008. Formation of stable submicron protein particles by thin film freezing. Pharm Res 25(6):1334-1346.
46. Souillac PO, Middaugh CR, Rytting JH. 2002. Investigation of protein/carbohydrate interactions in the dried state. 2. Diffuse reflectance FTIR studies. Int J Pharm 235:207-218.
47. Carpenter JF, Chang BS, Randolph TW. 2005. Physical damage to proteins during freezing, drying and rehydration. In Lyophilization of biopharmaceuticals; Costantino HR, Pikal MJ, Eds. AAPS Press, Arlington, VA; pp 423-442.
48. Timasheff SN. 1992. Stabilization of protein structure by solvent additives. In Stability of protein pharmaceuticals: Part B; Ahern TJ, Manning MC, Eds. Springer, pp 265-285.
49. Carpenter JF, Izutsu K-I, Randolph TW. 2004. Freezing and drying induced perturbations of protein structure and mechanisms of protein protection by stabilizing additives. In Freeze drying/lyophilization of pharmaceutical and biological products; Rey L, May JC, Eds. New York: Marcel Dekker, Inc., pp 147-186.
50. Allison SD, Chang BS, Randolph TW, Carpenter JF. 1999. Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding. Arch Biochem Biophys 365(2):289-298.
51. Webb SD, Cleland JL, Carpenter JF, Randolph TW. 2003. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-γ. J Pharm Sci 92(4):715-729.
52. Yu Z, Garcia AS, Johnston KP, Williams III RO. 2004. Spray freezing into liquid nitrogen for highly stable protein nanostructured microparticles. Eur J Pharm Biopharm 58:529-537.
53. Kueltzo LA, Wang W, Randolph TW, Carpenter JF. 2008. Effects of solution conditions, processing parameters and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci 97(5):1801-1812.
54. Costantino HR, Firouzabadian L, Hogeland K, Wu CC, Beganski C, Carrasquillo KG, Cordova M, Griebenow K, Zale SE, Tracy MA. 2000. Protein spray-freeze drying. Effect of atomization conditions on particle size and stability. Pharm Res 17:1374-1383.
55. Engstrom JD, Simpson DT, Lai ES, Williams III RO, Johnston KP. 2007. Morphology of protein particles produced by spray freezing of concentrated solutions. Eur J Pharm Biopharm 65:149-162.
56. Maa Y-F, Prestrelski SJ. 2000. Biopharmaceutical powders: particle formation and formulation considerations. Curr Pharm Biotechnol 1:283-302.
57. Kulkarni AM, Chatterjee AP, Schweizer KS, Zukoski CF. 2000. Effects of polyethylene glycol on protein interactions. J Chem Phys 113(21):9863-9873.
58. Lu PJ, Zaccarelli E, Ciulla F, Schofield AB, Sciortino F, Weitz DA. 2008. Gelation of particles with short-range attraction. Nature 453:499-503.
59. Boncina M, Rescic J, Vlachy V. 2008. Solubility of lysozyme in polyethylene glycol-electrolyte mixtures: The depletion interaction and ion-specific effects. Biophys J 95:1285-1294.
60. Shulgin IL, Ruckenstein E. 2006. Preferential hydration and solubility of proteins in aqueous solutions of polyethylene glycol. Biophys Chem 120:188-198.
61. Hiemenz PC, Rajagopalan R. 1997. Principles of colloid and surface chemistry. 3rd ed. New York: Marcel Dekker, Inc., pp 650.
62. Porcar L, Falus P, Chen W-R, Faraone A, Fratini E, Hong K, Baglioni P, Liu Y. 2010. Formation of the dynamic clusters in concentrated lyoszyme protein solutions. J Phys Chem Lett 1:126-129.
63. Lafleche F, Durand D, Nicolai T. 2003. Association of adhesive spheres formed by hydrophobically end-capped PEF. 1. Influence of the presence of single end-capped PEO. Macromolecules 36:1331-1340.
64. Kanai S, Liu J, Patapoff TW, Shire SJ. 2008. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci 97(10):4219-4227.
65. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. 2007. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 96(2):268-279.
66. Saluja A, Kalonia DS. 2008. Nature and consequences of protein-protein interactions in high protein concentration solutions. Int J Pharm 358:1-15.
67. Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink M. 2007. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem 282(4):2229-2236.
68. Pincus DL, Thirumalai D. 2009. Crowding effects on the mechanical stability and unfolding pathways of ubiquitin. J Phys Chem B 113:359-368.
69. Desai UR, Klibanov AM. 1995. Assessing the structural integrity of a lyophilized protein in organic solvents. J Am Chem Soc 117:3940-3945.
70. Roberts CJ, Debenedetti PG. 2002. Engineering pharmaceutical stability with amorphous solids. AIChE J 48(6):1140-1144.
71. Krishnan S, Chi EY, Webb JN, Chang BS, Shan D, Goldenberg M, Manning MC, Randolph TW, Carpenter JF. 2002. Aggregation of granulocyte colony stimulating factor under physiological conditions: Characterization and thermodynamic inhibition. Biochemistry 41:6422-6431.
72. Zhou H-X, Rivas G, Minton AP. 2008. Macromolecular crowding and confinement: Biochemical, biophysical and potential physiological consequences. Annu Rev Biophys 37:375-397.
73. Wang W, Wang EQ, Balthasar JP. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548-558.
74. Tabrizi MA, Tseng CM, Roskos LK. 2006. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11(1-2):81-88.